Skip to main content

Table 2 Mean changes in weight and laboratory values

From: Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia

 

OLZ LAI 150 (N = 140) Mean (SD)

OLZ LAI 405 (N = 318) Mean (SD)

OLZ LAI 300 (N = 141) Mean (SD)

R-Square

Regression Slope

Regression p-value

Jonckheere-Terpstra p-value

Effect Sizes

        

High vs. Low (95% C.I.)

Medium vs. Low (95% C.I.)

High vs. Medium (95% C.I.)

Weight (kg)

0.67 (4.38)

0.89 (3.87)

1.70 (4.14)

0.0086

0.10

.024

.034

0.264

0.063

0.201

in lbs:

1.47 (9.64)

1.96 (8.51)

3.74 (9.11)

       

Fasting glucose (mmol/L)

0.14 (1.36)

0.17 (1.29)

0.22 (1.19)

0.0005

0.01

.642

.092

0.049

0.016

0.033

in mg/dL:

2.52 (24.50)

3.06 (23.24)

3.96 (21.44)

       

Fasting HDL (mmol/L)

-0.00 (0.22)

0.00 (0.24)

-0.05 (0.24)

0.0064

-0.01

.094

.215

0.196

0.022

0.218

in mg/dL:

-0.00 (8.49)

0.00 (9.27)

-1.93 (9.27)

       

Fasting LDL (mmol/L)

-0.04 (0.57)

-0.07 (0.64)

0.02 (0.73)

0.0015

0.01

.423

.169

0.078

0.041

0.119

in mg/dL:

-1.54 (22.01)

-2.70 (24.71)

0.77 (28.19)

       

Fasting total cholesterol (mmol/L)

-0.12 (0.65)

-0.07 (0.73)

0.01 (0.78)

0.0037

0.01

.199

.240

0.165

0.065

0.100

in mg/dL:

-4.63 (25.10)

-2.70 (28.19)

0.39 (30.12)

       

Fasting triglycerides (mmol/L)

-0.18 (1.84)

-0.03 (1.23)

0.03 (1.19)

0.0022

0.02

.324

.958

0.147

0.107

0.039

in mg/dL:

-15.93 (162.83)

-2.65 (108.85)

2.65 (105.31)

       

Prolactin (μg/L):

          

All patients

-5.61 (12.49)

-2.76 (19.02)

3.58 (33.78)

0.0209

0.87

.001

<.001

0.410

0.127

0.283

Females

-8.27 (16.1)

-2.86 (30.31)

4.33 (23.16)

0.0294

1.16

.026

<.001

0.493

0.212

0.281

Males

-3.88 (9.17)

-2.72 (9.65)

3.16 (38.56)

0.0159

0.70

.025

.018

0.347

0.047

0.300

  1. Abbreviations: OLZ LAI = olanzapine long-acting injection; OLZ LAI 150 = group receiving low-dose olanzapine LAI, 150 mg every 2 weeks, approximate oral equivalent 10 mg/day (N = 140); OLZ LAI 405 = group receiving medium-dose olanzapine LAI, 405 mg every 4 weeks, approximate oral equivalent 15 mg/day (N = 318); and OLZ LAI 300 = group receiving high-dose olanzapine LAI, 300 mg every 2 weeks, approximate oral equivalent 20 mg/day (N = 141); HDL = high-density lipoprotein cholesterol; LDL = low-density lipoprotein cholesterol.